Business
Latigo Raises $345.6M in Upsized IPO for Non-Opioid Pain
Latigo Biotherapeutics raised $345.6 million in an upsized initial public offering, pricing at the top end of a marketed range and issuing 19.2 million…
Latigo Biotherapeutics raised $345.6 million in an upsized initial public offering, pricing at the top end of a marketed range and issuing 19.2 million…
Odyssey Therapeutics has filed for a U.S. initial public offering, joining a broader trend of drug developers pursuing public listings amid ongoing investor appetite…
Boehringer Ingelheim has received approval from U.S. regulatory authorities for its new drug aimed at treating a difficult form of lung cancer. This authorization…